[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-353126-105":59,"doc-detail-353126-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","detection-of-bladder-cancer-in-patients-with-microscopic-hematuria-using-oncuriadetect-results-of-a-prospective-multicenter-international-study","Detection of bladder cancer in patients with microscopic hematuria using OncuriaDetect - results of a prospective, multicenter international study","","Microscopic hematuria affects up to 10% of the general population and triggers costly evaluation to rule out bladder cancer. Oncuria-Detect is a 10-plex immunoassay that detects de novo bladder cancer by generating a protein biomarker signature from a single voided urine sample. This prospective multicenter analysis compares Oncuria-Detect’s diagnostic performance with the single-analyte BladderChek urine assay and urine cytology for identifying urothelial cancer in patients with microscopic hematuria.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/detection-of-bladder-cancer-in-patients-with-microscopic-hematuria-using-oncuriadetect-results-of-a-prospective-multicenter-international-study/353126/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/detection-of-bladder-cancer-in-patients-with-microscopic-hematuria-using-oncuriadetect-results-of-a-prospective-multicenter-international-study/353126.png","ImageObject",300,407,{"name":92,"@type":93},"Jasmine","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does Oncuria-Detect target in patients with microscopic hematuria?","Question",{"text":112,"@type":113},"Microscopic hematuria occurs in up to 10% of the general population and requires costly evaluation to ensure no bladder cancer exists. Oncuria-Detect aims to provide a noninvasive way to identify bladder cancer presence and risk-stratify patients.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the study designed and what reference standard was used?",{"text":117,"@type":113},"From September 2018 through July 2025, 9 medical facilities in the US and Japan enrolled 321 participants, with 292 deemed eligible. The reference standard for bladder cancer diagnosis was cystoscopy with biopsy.",{"name":119,"@type":110,"acceptedAnswer":120},"How did Oncuria-Detect perform compared with BladderChek and urine cytology?",{"text":121,"@type":113},"Oncuria-Detect showed 82.0% sensitivity and 97.5% negative predictive value. Compared to it, BladderChek had 9.3% sensitivity and 95.4% NPV, while cytology had 44.8% sensitivity and 97.2% NPV.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},353126,1790211946,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":46,"preview_page_count":19,"preview_urls":144},2336478487870,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Lotan etal. Journal of Translational Medicine (2026) 24:791  \n[https://doi.org/10.1186/s12967-026-08245-4](https://doi.org/10.1186/s12967-026-08245-4)  \nJournal of Translational Medicine  \nRESEARCH Open Access  \nDetection of bladder cancer in patients with microscopic hematuria using OncuriaDetect: results of a prospective, multicenter international study  \nYair Lotan1, Satoshi Anai2, Howard Kim3, Greg Gin4, Arash Akhavein3, Makito Miyake5, Michael Luu6, Michael Ahdoot3, Edward Messing7, Garry Peers8, Andrew Chen3, Ariel Moradzadeh3, Arnold I. Chin9, Menghan Liu 10, Sunao Tanaka6, Sergei Tikhonekov11,12, Ian Pagano13, Yingye Zheng10, Zhen Zhang14, Hideki Furuya6† and Charles J. Rosser3,15*†  \nAbstract  \nBackground Microscopic hematuria occurs in up to 10% of the general population and initiates costly evaluation to ensure no bladder cancer exists. Oncuria-Detect is a 10-plex immunoassay that detects de novo bladder cancer by generating a protein biomarker signature from a single voided urine sample. This report details the analysis of our prospective study that compares the diagnostic performance of the multiplex Oncuria-Detect assay to that of the single-analyte (i. e., NMP22) BladderChek™ urine assay and urine cytology for identifying bladder/urothelial cancer inpatients with microscopic hematuria.  \nMethods From September 2018 through July 2025, 9 medical facilities in the US and Japan prospectively enrolled 321 participants of whom 292 were deemed eligible. The bladder cancer diagnostic reference standard was cystoscopy with biopsy. Pre-cystoscopy, patients provided a urine sample for analysis by Oncuria-Detect and BladderChek™ (analyzed in a blinded manner) as well as urine cytology.  \nResults Bladder cancer was diagnosed in 22 patients (7 . 5%) . The Oncuria-Detect assay had the following performance characteristics 82 . 0% sensitivity and 97. 5% negative predictive value (NPV) compared to BladderChek™(9 . 3% sensitivity and 95 .4% NPV) and cytology (44 . 8% sensitivity and 97. 2% NPV) . Oncuria-Detect displayed favorable sensitivity for identifying early-and late-stage cancer. Oncuria-Detect had a favourable performance in detecting high-grade and MIBC (i. e., aggressive cancers); high-grade sensitivity was 93 . 5%(95%CI: 0 .783–1. 000) and MIBC sensitivity was 100. 0%(95%CI: 1.000–1. 000) compared to BladderChek™ high-grade sensitivity of 13. 8%(95%CI:  \n0.000–0. 370) and MIBC sensitivity was 0 . 0%(95%CI: 0 .000–0. 000) and cytology high-grade sensitivity was 60. 1%(95%CI: 0 .333–0. 852) and MIBC sensitivity was 73. 9%(95%CI: 0 .000–1. 000) .  \n†Hideki Furuya and Charles J. Rosser are co-senior authors.  \n*Correspondence: Charles J. Rosser [charles. rosser@cshs.org](charles. rosser@cshs.org)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/.)[.](http://creativecommons.org/licenses/by/4.0/.)  \nLotan et al. Journal of Translational Medicine (2026) 24:791 Page 2 of 8  \nConclusions In this analysis of an international prospective trial, Oncuria-Detect performed favorably in the noninvasive evaluat","cbCailVZ2LALFH9W","https://ap.wps.com/l/cbCailVZ2LALFH9W","pdf",1146632,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Background\n## Clinical rationale","[{\"question\":\"What problem does Oncuria-Detect target in patients with microscopic hematuria?\",\"answer\":\"Microscopic hematuria occurs in up to 10% of the general population and requires costly evaluation to ensure no bladder cancer exists. Oncuria-Detect aims to provide a noninvasive way to identify bladder cancer presence and risk-stratify patients.\"},{\"question\":\"How was the study designed and what reference standard was used?\",\"answer\":\"From September 2018 through July 2025, 9 medical facilities in the US and Japan enrolled 321 participants, with 292 deemed eligible. The reference standard for bladder cancer diagnosis was cystoscopy with biopsy.\"},{\"question\":\"How did Oncuria-Detect perform compared with BladderChek and urine cytology?\",\"answer\":\"Oncuria-Detect showed 82.0% sensitivity and 97.5% negative predictive value. Compared to it, BladderChek had 9.3% sensitivity and 95.4% NPV, while cytology had 44.8% sensitivity and 97.2% NPV.\"}]","Detection of bladder cancer in patients with microscopic hematuria using OncuriaDetect - results of a prospective, multicenter international study | PDF",1790103162,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b085de9d898a84cc5984e2a7e9a7ddf2.webp",983,1310,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fc5eb3bc5d7ba72ee3dfd4574911b27b.webp",982,1309,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/29bf1b693f4b534c4ba91e449df42922.webp",981,1308,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6c105beae2ec99dcee7b658fef4178af.webp",980,1306]